Stock listing

NASDAQ:ENLV Enlivex Ltd. Stock

Home listing (NASDAQ) of Enlivex Ltd.

Follow Enlivex Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:ENLV

$1.05 USD -0.15 (-12.5%)

Close on Nov 20, 2026

Past year -99.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.05 – $1.22 USDNov 20, 2026
Volume
39,970 sharesNov 20, 2026
Market cap
$1.61M USDAt the close on Nov 20, 2026 · price × 1.53M shares outstanding
52-week range
$1.00 – $434.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$45,475 USDMedian day 2,465 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Enlivex Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ENLV · Home$1.05 USD-0.15 (-12.5%)39,970$1.15$1.22$1.05$1.20Close on Nov 20, 2026
Frankfurt:1BT€1.05 EUR+0.02 (+1.9%)—€1.05€1.05€1.05€1.03Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENLV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.05-0.15-12.5%$1.15$1.22$1.0539,970
$1.20+0.05+4.3%$1.18$1.29$1.1639,667
$1.15+0.03+2.7%$1.15$1.18$1.1118,949
$1.12-0.07-5.9%$1.09$1.13$1.0065,712
$1.19-0.055-4.4%$1.30$1.312$1.1822,272
$1.245-0.015-1.2%$1.25$1.338$1.1920,750
$1.26+0.06+5.0%$1.20$1.27$1.1841,040
$1.20-0.17-12.4%$1.35$1.35$1.2047,127
$1.37+0.10+7.9%$1.28$1.41$1.2820,860
$1.270.000.0%$1.27$1.30$1.2318,131
$1.27-0.12-8.6%$1.38$1.40$1.2247,035
$1.39-0.07-4.8%$1.44$1.46$1.3724,093
$1.46+0.05+3.5%$1.43$1.56$1.4337,948
$1.41-0.37-20.8%$1.87$1.87$1.40137,600
$1.78-0.76-29.9%$2.47$2.47$1.73128,298
$2.54-0.07-2.7%$2.62$2.76$2.4649,834
$2.61-0.09-3.3%$2.71$2.765$2.5536,323
$2.70+0.097+3.7%$2.56$2.89$2.21580,489
$2.603-0.171-6.2%$2.774$2.798$2.56226,483
$2.774-0.413-13.0%$2.704$2.93$2.7042,574
$3.187-0.048-1.5%$3.138$3.278$3.0752,051
$3.235-0.344-9.6%$3.566$3.677$3.202,913
$3.579+0.261+7.9%$3.44$3.666$3.2821,748
$3.318+0.038+1.2%$3.379$3.638$3.082,373
$3.28-0.307-8.6%$3.685$3.734$3.2721,874
$3.587+0.138+4.0%$3.523$3.773$3.362,189
$3.45-0.109-3.1%$3.595$3.648$3.362,176
$3.558-0.49-12.1%$4.144$4.152$3.5393,414
$4.048-0.016-0.4%$4.16$4.214$3.9263,488
$4.064-0.368-8.3%$4.00$4.522$3.58410,874
$4.432-0.47-9.6%$5.312$6.88$4.085127,659
$4.902-0.541-9.9%$5.624$5.627$4.8015,230
$5.443-0.349-6.0%$5.979$6.046$5.4371,600
$5.792-0.405-6.5%$6.40$6.528$5.7711,659
$6.197-0.566-8.4%$6.789$6.878$6.082,465
$6.763-1.282-15.9%$7.872$8.029$6.5822,956
$8.045+0.363+4.7%$7.696$9.28$7.5223,798
$7.682-0.542-6.6%$8.32$8.48$7.522,296
$8.224-1.336-14.0%$9.60$9.60$8.0432,465
$9.56-0.131-1.4%$9.60$9.92$9.281,240
$9.691-0.549-5.4%$10.14$10.24$9.121,489
$10.24-0.102-1.0%$10.13$11.00$9.8422,321
$10.34-0.742-6.7%$11.04$11.34$9.1794,821
$11.08-1.821-14.1%$13.44$13.60$10.642,621
$12.91+1.27+10.9%$11.68$13.10$11.371,368
$11.64-1.342-10.3%$13.14$13.62$10.242,999
$12.98-1.146-8.1%$14.40$14.72$12.641,604
$14.12+0.291+2.1%$14.08$14.72$13.92896
$13.83-1.52-9.9%$15.20$16.32$13.821,190
$15.35-0.339-2.2%$16.00$17.12$15.201,000
$15.69-0.949-5.7%$16.48$16.96$15.681,100
$16.64-1.12-6.3%$17.92$19.47$16.321,124
$17.76+0.16+0.9%$17.60$19.04$16.96744
$17.60-0.96-5.2%$18.40$18.56$16.32985
$18.56-1.44-7.2%$20.00$20.40$18.081,148
$20.00-0.48-2.3%$20.64$20.80$19.36889
$20.480.000.0%$20.32$20.96$19.201,341
$20.48-1.12-5.2%$21.28$21.44$18.401,577
$21.60-2.00-8.5%$24.00$25.20$21.522,075
$23.60-0.64-2.6%$24.16$26.56$23.522,028
$24.24-0.08-0.3%$24.32$25.92$23.36585
$24.32+0.16+0.7%$23.84$25.12$23.36635
$24.16+0.64+2.7%$23.68$24.96$23.04581
$23.52-0.48-2.0%$23.84$24.32$22.24615
$24.00-3.68-13.3%$26.88$27.20$23.281,058

Splits

4 splits since 2017 · NASDAQ:ENLV · every price before a split is adjusted for it

DayRatioWhat
1-for-16Consolidation
1-for-15Consolidation
1-for-8Consolidation
1-for-5Consolidation
Ticker
NASDAQ:ENLV
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Enlivex Ltd. news

Enlivex Ltd. on 6ix

News releases
37 in the last 12 months · 151 in all · newest Nov 18, 2026 · oldest 2019
Decks
32 decks · latest Jun 24, 2026

Where Enlivex Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:ENLV · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A119KHLS ExchangeGermanyEUR
Lang & Schwarz:A119KHLang & SchwarzGermanyEUR
Frankfurt:1BTFrankfurtGermanyEUR
Tradegate:1BTTradegateGermanyEUR
BOATS:ENLVBOATSUnited StatesUSD
Stuttgart:1BTStuttgartGermanyEUR

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$13.34M USD
P/E
0.0×
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.67

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
1280.00 USD · Analysts' mean
EPS, year to Dec 2026
-18.40 · 1 analyst

Team and board

Officers

OfficerRole
Oren HershkovitzChief Executive Officer
Shachar ShlosbergerChief Financial Officer
Veronique Amor-BaroukhChief Operating Officer
Einat GalamidiChief Medical Officer
Shai NovikExecutive Chairman

Board

DirectorRole
Shai NovikExecutive Chairman
Matteo RenziDirector

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 20, 2026
Q2 2026Sep 25, 2026 · After close−14.0%
Q1 2026Jun 26, 2026−0.1%
Q4 2025Mar 25, 2026 · Before open+9.1%
Q3 2025Nov 14, 2025 · After close−1.6%
Q2 2025Aug 29, 2025 · After close+0.9%
Q1 2025May 30, 2025 · After close+0.4%
Q4 2024Mar 31, 2025−6.9%
Q3 2024Nov 29, 2024 · After close−5.3%
Q2 2024Aug 30, 2024 · After close−3.1%
All 20 quarters
QuarterResultsShare move
Q1 2024Jun 14, 2024 · After close−4.8%
Q4 2023Mar 29, 2024 · After close+5.5%
Q3 2023Nov 9, 2023 · After close+2.3%
Q2 2023Jul 31, 2023 · Before open+2.8%
Q1 2023Jun 16, 2023 · After close−1.0%
Q4 2022Mar 31, 2023 · After close+1.9%
Q3 2022Dec 2, 2022 · After close−1.4%
Q2 2022Aug 22, 2022 · Before open+3.3%
Q1 2022May 27, 2022 · After close+6.1%
Q3 2021Nov 19, 2021 · After close−7.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (June 2026)Investor deck25 slidesJun 24, 2026
Investor Presentation (June 2026)Investor deck35 slidesJune 2026
Investor Presentation (March 2026)Investor deck26 slidesMar 24, 2026
Enlivex Therapeutics — Investor Presentation (November 2025)Investor deck26 slidesNov 24, 2025
Investor Presentation (November 2025)Investor deck24 slidesNovember 2025
Investor Presentation (November 2025)Investor deck30 slidesNovember 2025
Investor Presentation (October 2025)Investor deck37 slidesOctober 2025
Enlivex Therapeutics — Investor Presentation (September 2025)Investor deck39 slidesSeptember 2025
Enlivex Therapeutics — Investor Presentation (August 2025)Investor deck26 slidesAug 18, 2025
Enlivex Therapeutics — Investor Presentation (June 2025)Investor deck39 slidesJune 2025
All 32 decks
DeckKindSlidesDate
Enlivex Therapeutics — Investor Presentation (March 2025)Investor deck39 slidesMarch 2025
Enlivex Therapeutics — Investor Presentation (January 2025)Investor deck39 slidesJanuary 2025
Enlivex Therapeutics — Investor Presentation (June 2024)Investor deck36 slidesJune 2024
Enlivex Therapeutics — Investor Presentation (April 2024)Investor deck34 slidesApr 11, 2024
Enlivex Therapeutics — Investor Presentation (February 2024)Investor deck30 slidesFebruary 2024
Enlivex Therapeutics — Investor Presentation (September 2023)Investor deck32 slidesSeptember 2023
Enlivex Therapeutics — Investor Presentation (April 2023)Investor deck62 slidesApril 2023
Enlivex Therapeutics — Investor Presentation (December 2022)Investor deck61 slidesDecember 2022
Enlivex Therapeutics — Investor Presentation (November 2022)Investor deck55 slidesNov 15, 2022
Enlivex Therapeutics — Investor Presentation (September 2022)Investor deck55 slidesSep 12, 2022
Enlivex Therapeutics — Investor Presentation (July 2022)Investor deck45 slidesJul 25, 2022
Enlivex Therapeutics — Investor Presentation (May 2022)Investor deck45 slidesMay 31, 2022
Enlivex Therapeutics — Investor Presentation (November 2021)Investor deck38 slidesNovember 2021
Enlivex Therapeutics — Investor Presentation (August 2021)Investor deck37 slidesAugust 2021
Enlivex Therapeutics — Investor Presentation (April 2021)Investor deck37 slidesApril 2021
Enlivex Therapeutics — Investor Presentation (February 2021)Investor deck36 slidesFebruary 2021
Enlivex Therapeutics — Investor Presentation (January 2021)Investor deck35 slidesJanuary 2021
Enlivex Therapeutics — Investor Presentation (December 2020)Investor deck38 slidesDecember 2020
Enlivex Therapeutics — Investor Presentation (June 2020)Investor deck35 slidesJune 2020
Enlivex Therapeutics — ISCT 2020, Paris (Virtual)Conference14 slidesMay 28, 2020
Enlivex Therapeutics — Investor Presentation (September 2019)Investor deck26 slidesSep 9, 2019
Bioblast Pharma — Merger or Acquisition (December 2018)Merger or acquisition12 slidesDec 6, 2018

Open Decks

Financings

RaiseDate
Registered direct offering of ordinary shares (or pre-funded warrants) with accompanying ordinary warrants
Announced: US$7.5M · US$1.315 a share · Warrants at US$1.578 for 36 months
Use of proceeds: Clinical, regulatory, manufacturing and R&D activities; potential acquisitions and in-licensing; general corporate purposes
Nov 16, 2026
Private placement of ordinary shares
Cancelled: US$400M · US$6 a share
Buyers: Rain Foundation (66,666,667 ordinary shares, to be paid for using RAIN tokens (agreement terminated))
Use of proceeds: Treasury strategy built around the Rain protocol prediction markets, while continuing to advance its Allocetra immunotherapy for age-related osteoarthritis
Sep 22, 2026
Private placement of ordinary shares (or ordinary share equivalents)
Closed: US$212M raised · US$1 a share · BTIG
Dealers: BTIG (lead)
Use of proceeds: Implement a RAIN prediction markets token treasury strategy while continuing core business operations
Nov 26, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as BIO BLAST PHARMA LTD. Priced at US$11.00 a share on Jul 30, 2014.

Price
US$11.00 a share
Shares offered
3,200,000 ordinary shares
Offering size
US$35.2 million
Underwriters' option
Up to 480,000 more shares
Underwriters
Oppenheimer & Co., Roth Capital Partners, BTIG · In the order on the cover
Shares delivered
On or about Aug 5, 2014

Steps

StepWhen
Filed publiclyFeb 7, 2014
Amended 5 timesNewest Jul 25, 2014
Shares registered with an exchangeJul 28, 2014
Declared effective by the SECJul 30, 2014
Final prospectus, with the priceJul 31, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000002.28M0000
Cost of revenue332.0K545.0K835.0K777.0K546.0K286.0K297.0K121.0K12.0K25.0K
Gross profit-332.0K-545.0K-835.0K-777.0K-546.0K-286.0K-297.0K-121.0K-12.0K-25.0K
Research and development9.20M10.6M19.0M18.7M12.9M6.09M5.60M4.01M1.69M8.88M
Selling, general and administrative5.68M4.91M6.14M6.70M6.24M3.60M2.75M937.0K2.96M6.99M
Operating income-15.0M-15.9M-29.4M-25.8M-19.3M-9.79M-8.62M-5.30M-2.17M-15.9M
Depreciation and amortization332.0K545.0K835.0K777.0K546.0K286.0K206.0K121.0K83.0K38.0K
EBITDA-14.7M-15.3M-28.6M-25.0M-18.7M-9.50M-8.41M-5.18M-2.09M-15.8M
Interest expense13.0K13.0K14.0K5.26M328.0K6.00K7.00K3.00K00
Income before tax1.62B-15.0M-29.1M-31.1M14.5M11.8M9.38M-2.12M-5.92M-15.8M
Income tax382.6M4.24M11.3M-4.82M2.04M765.0K-4.00K28.0K216.0K
Net income1.24B-15.0M-29.1M-31.1M-14.5M-11.8M-9.38M-4.24M-2.50M-16.0M
Earnings per share, basic27.04-0.73-1.56-1.69-0.81-0.90-1.11-1.40-0.94-40.13
Earnings per share, diluted25.48-0.73-1.56-1.69-0.81-0.90-1.11-1.40-0.94-40.13

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.89M3.30M813.0K49.9M11.2M5.67M3.95M9.74M9.03M3.04M
Short-term investments3.86M198.0K5.11M299.0K62.9M30.0M8.06M40.0K3.01M
Receivables235.0K1.30M229.0K647.0K1.09M1.24M2.40M16.0K28.0K52.0K
Inventory-229.0K1.18M-12.2M-31.2M1.50M
Current assets1.74B26.0M33.8M52.3M86.4M38.1M16.4M10.3M3.62M10.5M
Property, plant and equipment361.0K625.0K1.54M9.88M2.53M1.48M648.0K685.0K388.0K71.0K
Total assets2.33B27.7M36.8M67.6M95.1M40.4M17.6M11.0M3.62M10.6M
Accounts payable3.81M811.0K827.0K1.95M878.0K463.0K316.0K173.0K19.0K32.0K
Current liabilities9.02M3.80M6.06M6.61M4.72M4.37M5.98M1.13M460.0K1.93M
Total debt641.0K534.0K1.03M4.85M6.01M203.0K123.0K
Total liabilities392.1M4.10M6.75M10.8M10.1M4.87M6.28M1.33M1.05M1.93M
Shareholders' equity1.93B23.6M30.1M56.8M85.0M35.5M11.3M9.71M8.49M2.81M
Shares outstanding237.4M23.7M18.6M18.4M18.3M14.6M10.3M3.51M418.5K3.28M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.4M-13.0M-23.5M-24.0M-17.5M-11.0M-7.04M-3.16M-2.30M-15.5M
Capital spending-68.0K-103.0K-236.0K-8.12M-1.63M-1.02M-193.0K-461.0K-130.0K-18.0K
Free cash flow-10.5M-13.1M-23.8M-32.1M-19.2M-12.0M-7.23M-3.62M-2.43M-15.5M
Cash from investing-1.32M9.06M-26.0M62.5M-38.4M-21.0M-6.36M-501.0K-130.0K8.98M
Cash from financing10.4M6.45M360.0K150.0K61.0M33.1M8.31M5.19M8.05M6.09M
Share buybacks8.31M1.00K6.09M
Change in cash-1.36M2.50M-49.1M38.7M5.03M1.10M-5.09M1.53M5.62M-415.0K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerNov 17, 2026Current reportSEC
6-K · Report of a foreign issuerNov 17, 2026Current reportSEC
424B5 · ProspectusNov 17, 2026Offer documentSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
6-K · Report of a foreign issuerNov 2, 2026Current reportSEC
6-K · Report of a foreign issuerOct 28, 2026Current reportSEC
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
6-K · Report of a foreign issuerOct 22, 2026Current reportSEC
6-K · Report of a foreign issuerOct 19, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K/A · Report of a foreign issuer, amendedOct 2, 2026Current reportSEC
6-K/A · Report of a foreign issuer, amendedSep 30, 2026Current reportSEC
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
6-K · Report of a foreign issuerSep 25, 2026Current reportSEC
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
424B3 · ProspectusAug 14, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 14, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 11, 2026Current reportSEC
F-3 · Registration statementAug 6, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 30, 2026Current reportSEC
6-K · Report of a foreign issuerJul 29, 2026Current reportSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 13, 2026Current reportSEC
6-K · Report of a foreign issuerJul 7, 2026Current reportSEC
6-K · Report of a foreign issuerJun 24, 2026Current reportSEC
6-K · Report of a foreign issuerJun 22, 2026Current reportSEC
6-K · Report of a foreign issuerMay 28, 2026Current reportSEC
6-K · Report of a foreign issuerMay 27, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 15, 2026Current reportSEC
424B3 · ProspectusMay 1, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 1, 2026Other filingsSEC
CORRESP · Letter to the SECApr 28, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 27, 2026Other filingsSEC
F-3 · Registration statementApr 21, 2026Offer documentSEC
6-K · Report of a foreign issuerApr 21, 2026Current reportSEC
6-K · Report of a foreign issuerApr 8, 2026Current reportSEC
6-K · Report of a foreign issuerMar 26, 2026Current reportSEC
20-F · Annual reportMar 25, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 25, 2026Current reportSEC
6-K · Report of a foreign issuerMar 24, 2026Current reportSEC
6-K · Report of a foreign issuerMar 23, 2026Current reportSEC
424B3 · ProspectusMar 20, 2026Offer documentSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 13, 2026Offer documentSEC
6-K · Report of a foreign issuerFeb 23, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 10, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 5, 2026Current reportSEC
6-K · Report of a foreign issuerJan 26, 2026Current reportSEC
6-K · Report of a foreign issuerJan 23, 2026Current reportSEC
6-K · Report of a foreign issuerJan 7, 2026Current reportSEC
424B3 · ProspectusJan 6, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 5, 2026Other filingsSEC
CORRESP · Letter to the SECDec 30, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 29, 2025Other filingsSEC
F-3 · Registration statementDec 23, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 18, 2025Current reportSEC
6-K · Report of a foreign issuerDec 4, 2025Current reportSEC
6-K · Report of a foreign issuerNov 26, 2025Current reportSEC
6-K · Report of a foreign issuerNov 24, 2025Current reportSEC
424B5 · ProspectusNov 24, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 24, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
6-K · Report of a foreign issuerNov 14, 2025Current reportSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
6-K · Report of a foreign issuerSep 25, 2025Current reportSEC
6-K · Report of a foreign issuerSep 11, 2025Current reportSEC
6-K · Report of a foreign issuerSep 9, 2025Current reportSEC
6-K · Report of a foreign issuerAug 29, 2025Current reportSEC
6-K · Report of a foreign issuerAug 18, 2025Current reportSEC
6-K · Report of a foreign issuerAug 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 14, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
6-K · Report of a foreign issuerMay 30, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
424B3 · ProspectusMay 13, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 13, 2025Other filingsSEC
CORRESP · Letter to the SECMay 8, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 7, 2025Other filingsSEC
F-3 · Registration statementMay 2, 2025Offer documentSEC
20-F · Annual reportApr 30, 2025Annual reportSEC
6-K · Report of a foreign issuerApr 23, 2025Current reportSEC
6-K · Report of a foreign issuerApr 21, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
6-K · Report of a foreign issuerMar 31, 2025Current reportSEC
6-K · Report of a foreign issuerMar 17, 2025Current reportSEC
6-K · Report of a foreign issuerMar 4, 2025Current reportSEC
6-K · Report of a foreign issuerMar 3, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerDec 11, 2024Current reportSEC
6-K · Report of a foreign issuerDec 3, 2024Current reportSEC
6-K · Report of a foreign issuerNov 29, 2024Current reportSEC
6-K · Report of a foreign issuerNov 20, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 8, 2024Current reportSEC
6-K · Report of a foreign issuerOct 31, 2024Current reportSEC
6-K · Report of a foreign issuerOct 30, 2024Current reportSEC
6-K/A · Report of a foreign issuer, amendedOct 15, 2024Current reportSEC
6-K · Report of a foreign issuerSep 26, 2024Current reportSEC
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
6-K · Report of a foreign issuerSep 11, 2024Current reportSEC
6-K · Report of a foreign issuerAug 30, 2024Current reportSEC
6-K · Report of a foreign issuerJul 23, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
6-K · Report of a foreign issuerJun 17, 2024Current reportSEC
6-K · Report of a foreign issuerJun 14, 2024Current reportSEC
6-K · Report of a foreign issuerJun 3, 2024Current reportSEC
6-K · Report of a foreign issuerMay 29, 2024Current reportSEC
424B5 · ProspectusMay 29, 2024Offer documentSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
20-F · Annual reportApr 30, 2024Annual reportSEC
6-K · Report of a foreign issuerApr 29, 2024Current reportSEC
6-K · Report of a foreign issuerApr 22, 2024Current reportSEC
6-K · Report of a foreign issuerApr 16, 2024Current reportSEC
6-K · Report of a foreign issuerApr 11, 2024Current reportSEC
6-K · Report of a foreign issuerMar 29, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 7, 2024Current reportSEC
6-K · Report of a foreign issuerJan 22, 2024Current reportSEC
6-K · Report of a foreign issuerJan 17, 2024Current reportSEC
6-K · Report of a foreign issuerDec 20, 2023Current reportSEC
6-K · Report of a foreign issuerNov 9, 2023Current reportSEC
6-K · Report of a foreign issuerNov 7, 2023Current reportSEC
6-K · Report of a foreign issuerNov 2, 2023Current reportSEC
6-K · Report of a foreign issuerOct 26, 2023Current reportSEC
6-K · Report of a foreign issuerSep 18, 2023Current reportSEC
6-K · Report of a foreign issuerSep 13, 2023Current reportSEC
6-K · Report of a foreign issuerSep 11, 2023Current reportSEC
6-K · Report of a foreign issuerSep 1, 2023Current reportSEC
6-K · Report of a foreign issuerAug 2, 2023Current reportSEC
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
6-K · Report of a foreign issuerJun 26, 2023Current reportSEC
6-K · Report of a foreign issuerJun 16, 2023Current reportSEC
6-K · Report of a foreign issuerMay 31, 2023Current reportSEC
6-K · Report of a foreign issuerMay 8, 2023Current reportSEC
6-K · Report of a foreign issuerApr 19, 2023Current reportSEC
6-K · Report of a foreign issuerApr 17, 2023Current reportSEC
20-F · Annual reportApr 10, 2023Annual reportSEC
6-K · Report of a foreign issuerApr 4, 2023Current reportSEC
6-K · Report of a foreign issuerApr 3, 2023Current reportSEC
6-K · Report of a foreign issuerMar 31, 2023Current reportSEC
6-K · Report of a foreign issuerMar 20, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 15, 2023Current reportSEC
6-K · Report of a foreign issuerJan 25, 2023Current reportSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerDec 30, 2022Current reportSEC
424B5 · ProspectusDec 30, 2022Offer documentSEC
6-K · Report of a foreign issuerDec 5, 2022Current reportSEC
6-K · Report of a foreign issuerDec 2, 2022Current reportSEC
6-K · Report of a foreign issuerNov 28, 2022Current reportSEC
6-K · Report of a foreign issuerNov 15, 2022Current reportSEC
6-K · Report of a foreign issuerOct 5, 2022Current reportSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
6-K · Report of a foreign issuerSep 6, 2022Current reportSEC
6-K · Report of a foreign issuerAug 29, 2022Current reportSEC
6-K · Report of a foreign issuerAug 24, 2022Current reportSEC
6-K · Report of a foreign issuerAug 22, 2022Current reportSEC
6-K · Report of a foreign issuerAug 17, 2022Current reportSEC
6-K · Report of a foreign issuerAug 3, 2022Current reportSEC
6-K · Report of a foreign issuerJul 6, 2022Current reportSEC
6-K · Report of a foreign issuerJun 6, 2022Current reportSEC
6-K · Report of a foreign issuerMay 31, 2022Current reportSEC
6-K · Report of a foreign issuerMay 27, 2022Current reportSEC
6-K · Report of a foreign issuerMay 25, 2022Current reportSEC
6-K · Report of a foreign issuerMay 23, 2022Current reportSEC
6-K · Report of a foreign issuerMay 9, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveMay 6, 2022Other filingsSEC
6-K · Report of a foreign issuerMay 5, 2022Current reportSEC
CORRESP · Letter to the SECMay 3, 2022Other filingsSEC
UPLOAD · Letter from the SECMay 2, 2022Other filingsSEC
6-K · Report of a foreign issuerApr 29, 2022Current reportSEC
F-3 · Registration statementApr 29, 2022Offer documentSEC
20-F · Annual reportApr 29, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 8, 2022Current reportSEC
6-K · Report of a foreign issuerFeb 22, 2022Current reportSEC
6-K · Report of a foreign issuerDec 13, 2021Current reportSEC
6-K · Report of a foreign issuerDec 7, 2021Current reportSEC
6-K · Report of a foreign issuerDec 6, 2021Current reportSEC
6-K · Report of a foreign issuerNov 22, 2021Current reportSEC
6-K · Report of a foreign issuerNov 19, 2021Current reportSEC
6-K · Report of a foreign issuerNov 10, 2021Current reportSEC
6-K · Report of a foreign issuerNov 4, 2021Current reportSEC
6-K · Report of a foreign issuerOct 5, 2021Current reportSEC
6-K · Report of a foreign issuerOct 4, 2021Current reportSEC
6-K · Report of a foreign issuerSep 30, 2021Current reportSEC
6-K · Report of a foreign issuerSep 22, 2021Current reportSEC

This page holds 200 of 424 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Enlivex Ltd.’s releases · as of Nov 16, 2026

Common shares
1,531,994
Fully diluted
1,531,994

Fully diluted

LineShares
Common shares1,531,994

Share count over time

CountShares
Nov 22, 20261,531,994
Oct 22, 2026
Jul 7, 2026

Open Cap table

Shareholders

HolderSharesValueAs of
Fidelity Nasdaq Composite Index Fund136KUS$110KMay 31, 2026
Invesco NASDAQ Future Gen 200 ETF66,818US$54,143May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Roger Pomerantz
Other companies: Indaptus Therapeutics, Inc. (Director · Since at least Sep 30, 2022); Viracta Therapeutics Inc (Director · May 25, 2022 – Nov 25, 2024 · Past)
Director · Since at least Mar 18, 2026
Avraham Havron
Other companies: CollPlant Biotechnologies Ltd. (Director · Since at least Mar 18, 2026)
Director · Since at least Mar 18, 2026
Einat GalamidiChief Medical Officer · Since at least Mar 18, 2026
Matteo RenziDirector · Since at least Nov 24, 2025
Oren HershkovitzChief Executive Officer · Since at least Mar 18, 2026
Shachar ShlosbergerChief Financial Officer · Since at least Mar 18, 2026
Shai NovikDirector · Since at least Mar 18, 2026
Veronique Amor-BaroukhChief Operating Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Enlivex Ltd.